Cambrian Bioworks, a biotechnology company, has raised $1.45 million in a seed funding round led by the Irani family office. The round also saw participation from the company’s CEO and co-founder, Vaibhav Hegde.
The funding will be used for the development of Cambrian’s automated molecular diagnostics platforms, bolster R&D efforts, expand the team, and support forays into international markets.
Hari Prasad of Kyra Ventures, representing the lead investor, commented “We’re very excited to back Cambrian Bioworks in their mission to elevate medical diagnostics in India. This team is building products for niches that solve fundamental problems in healthcare delivery.”
Hegde, CEO and co-founder stated, “Molecular diagnostics is crucial for precise diagnosis, disease subtyping, and therapy selection in cancer care. This funding marks a significant milestone in our journey.”
The news follows the recent starting of Cambrian’s nucleic acid extraction platform, Manta. Manta provides DNA/RNA for genomics and PCR testing in hospitals and laboratories. Building on this, Cambrian aims to enable widespread access to automated devices for liquid biopsy testing and targeted sequencing.
Bengaluru-based Cambrian Bioworks, founded by Hegde, Rohit Asil, and Raghav Sridhar, specialises in automated molecular diagnostic platforms with applications in oncology, genomics, rare disease testing, and AMR detection.
